Recent Articles
Ibrutinib and Palbociclib: A New Combination for Mantle Cell Lymphoma?
The combination of ibrutinib and the CDK-4/6 inhibitor palbociclib could be safely administered to patients with previously treated mantle cell lymphoma (MCL), according to...
Caplacizumab Improves Platelet Normalization Time, Reduces Mortality in Acquired TTP
Adding caplacizumab to standard of care for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) shortened the time to the normalization of platelet counts...
An Ode to Joy
We have new leadership at my institution, who, in an act of inspiration (or accidental greatness), have declared that bringing joy back to the...
No Settlements as Federal Opioid Cases Move to Trial
Judge Dan Aaron Polster of the Northern District of Ohio will preside over three consolidated federal lawsuits against makers and distributors of opioids in...
PhRMA Calls Out Foreign Countries Over Patent and Pricing Policies
PhRMA, the pharmaceutical industry’s trade group, filed comments with the Office of the U.S. Trade Representative asking for “urgent action” against two dozen countries...
Current Issue
February 2019, Volume 5, Issue 3
This issue features a look at the unique challenges of developing treatments for orphan diseases, more coverage of the 2018 ASH annual meeting, and more.
